Jump to content

Drilldown: Medicines

Choose a table:


Medicines > classes : Analgesic or Classic Psychedelic or [[:Category:Antimetabolites|Antimetabolite (pyrimidine analog)]]

Use the filters below to narrow your results.

generic:
Codeine (2)
brand:
None (74) · (multiple, generic dominant) (1) · Darvon (1) · Delysid (historical, Sandoz, withdrawn 1965) (1) · Demerol (1) · Dilaudid (1) · Dolophine (1) · Duragesic (1) · Efudex (topical), Carac (topical), Fluoroplex (topical); generic IV (1) · Nubain (1) · Nucynta (1) · Opana (1) · Stadol (1) · Suboxone (1) · Talwin (1) · Vicodin (1)
classes: (Click arrow to add another value)
mechanism:
5-HT2A agonist (26) · Potent 5-HT2A agonist (5) · LSD analogue; 5-HT2A agonist (4) · Mu-opioid receptor agonist (4) · Prodrug of LSD; 5-HT2A agonist (4) · Potent mu-opioid receptor agonist (3) · Contains LSA (2) · Contains mescaline (2)
uses:
None (87) · Mild to moderate pain; cough suppression (low-dose). (1) · '"`UNIQ--vote-000011BA-QINU`"', '"`UNIQ--vote-000011BB-QINU`"', '"`UNIQ--vote-000011BC-QINU`"', '"`UNIQ--vote-000011BD-QINU`"' (1)
starting dose:
None (87) · Adult: 15–60 mg every 4 hours as needed. (1) · Topical: 0.5-5% cream/solution to lesions BID × 2-4 weeks; systemic IV: regimen-specific in cancer chemotherapy (1)
preparations:
None (87) · 0.5% (Carac), 1% (Fluoroplex), 5% (Efudex) topical creams/solutions; 50 mg/mL IV (1) · Tablet (15, 30, 60 mg); oral solution; combination products (with [[Acetaminophen|acetaminophen]] or ibuprofen). (1)
fda max:
None (87) · 360 mg/day (1) · Topical: nightly; systemic: regimen-specific (1)
routes:
None (86) · IV (1) · Oral (1) · PO (only formulation marketed in the US). (1) · Topical (1)
onset:
None (86) · 30–60 min (PO) (1) · 30–60 minutes (1) · Topical: inflammation, erythema, crusting at 2 weeks; complete response weeks to months after course (1)
duration:
None (86) · 4–6 hours (1) · 8–12 hours (1) · N/A (1)
halflife:
None (86) · 2.5–3 hours (1) · 3–5 hours (1) · ~10-20 minutes systemically (rapid hepatic and erythrocyte dihydropyrimidine dehydrogenase clearance)'"`UNIQ--ref-000011BE-QINU`"' (1)
bioavailability:
None (86) · 70–90% (oral) (1) · Topical: minimal systemic absorption (oral systemic 5-FU not used due to poor and variable absorption)'"`UNIQ--ref-000011BF-QINU`"' (1) · ~50% (variable, CYP2D6-dependent for analgesic effect). (1)
pregnancy:
None (86) · Avoid; risk of neonatal opioid withdrawal with chronic use; UM-mother breastfeeding contraindicated. (1) · Not established (1) · Topical: avoid; systemic: contraindicated in pregnancy.<sup class="pcp-cn" title="This claim needs a citation.">&#91;[[Pharmacopedia:Citation needed|citation&nbsp;needed]]&#93;</sup> (1)
legal:
None (86) · Schedule I (United States) (1) · US Schedule II (single-entity); Schedule III–V (combination products by content). (1) · [[USLegal:Prescription only|Rx-only]] in US (1)

Showing below up to 89 results in range #1 to #89.

View (previous 250 | next 250) (20 | 50 | 100 | 250 | 500)


View (previous 250 | next 250) (20 | 50 | 100 | 250 | 500)

Retrieved from "https://pharmacopedia.wiki/p/Special:Drilldown/Medicines"